CN218833279U - Combined immune-inflammation adsorption system - Google Patents
Combined immune-inflammation adsorption system Download PDFInfo
- Publication number
- CN218833279U CN218833279U CN202222334289.3U CN202222334289U CN218833279U CN 218833279 U CN218833279 U CN 218833279U CN 202222334289 U CN202222334289 U CN 202222334289U CN 218833279 U CN218833279 U CN 218833279U
- Authority
- CN
- China
- Prior art keywords
- plasma
- adsorption
- inflammatory
- adsorber
- column
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- External Artificial Organs (AREA)
Abstract
The utility model discloses a combined immune-inflammation adsorption system, which comprises an arterial blood end, a venous blood end and a plasma end, wherein a plasma separator is connected between the arterial blood end and the venous blood end; the input end of the plasma end is connected with the plasma separator, the output end is connected with the venous blood end, the plasma end is provided with a first plasma bypass and a second plasma bypass, the first plasma bypass is connected with the inflammation factor adsorber in series, and the second plasma bypass is connected with the reproducible immune adsorption column in series. In some examples of the utility model, the reproducible immune adsorption column and the inflammation factor adsorption column are integrated into one treatment unit, so that the immune adsorption and the inflammation factor adsorption treatment can be simultaneously completed, and the two reproducible immune adsorption columns are alternately adsorbed and regenerated, so that the treatment time can be saved; two or more inflammatory factor adsorption columns are connected in parallel and sequentially adsorb, so that the adsorption capacity is improved under the condition of not increasing the column pressure, and the requirements of different patients are met.
Description
Technical Field
The utility model belongs to the technical field of medical instrument, concretely relates to Combined immunity-inflammation Adsorption System (CIAS).
Background
Autoimmune diseases are a major challenge affecting global health. At present, over 3000 thousands of autoimmune disease patients exist in China, and the autoimmune disease treatment system relates to multiple fields of nerve immunity, rheumatism immunity, transplantation immunity, blood diseases and the like. Most autoimmune diseases are caused by pathogenic autoantibodies in patients, which can bind to self-antigens, damage their tissues by complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC), and the damaged tissues induce inflammatory reactions, further aggravating tissue damage, and further induce diseases. Autoantibodies are therefore the initiator and direct damaging molecule of the pathogenic process of autoimmune diseases, and inflammatory factors are also important players in the pathogenic process.
The plasmapheresis technology is a traditional technology for clearing autoantibodies, but is limited by plasma supply and has cross infection risk, so that the technology is difficult to popularize and use clinically. The reproducible immunoadsorption technology (such as protein A immunoadsorption technology) can rapidly and accurately remove autoantibodies, has larger adsorption capacity, can be flexibly adjusted according to the needs of patients, does not need to input exogenous plasma, can save a large amount of plasma resources, is rapidly popularized and used clinically at present, and gradually replaces plasma replacement. However, the immunoadsorption technology cannot eliminate inflammatory factors, and a new improvement and improvement are needed for the treatment effect of autoimmune diseases. In addition, the macroporous adsorption resin perfusion device which is used clinically has the function of adsorbing inflammatory factors.
The traditional clinical treatment technology generally separates the immunoadsorption and the inflammatory factor adsorption, particularly the reproducible immunoadsorption combines the inflammatory factor adsorption, and the immunoadsorption column needs to be reproduced in the treatment process, so that the immunoadsorption column is difficult to be clinically integrated into a treatment unit for completion. In clinical practice, it is considered that the immunoadsorption column cannot adsorb during the regeneration process, resulting in "wasted" treatment time. In addition, because the current inflammatory factor adsorption column cannot be regenerated, the adsorption capacity of a single adsorption column is limited, and the requirement of a patient with a high inflammatory factor level cannot be met, and the column pressure is increased due to the fact that two or more simple adsorption columns are connected in series, and the clinical practical operation is difficult to carry out.
Disclosure of Invention
The utility model aims to overcome at least one deficiency of the prior art, and provides a combined immune-inflammation adsorption system, which integrates a reproducible immune adsorption column and an inflammation factor adsorption column into one treatment unit for completion, and further, the immune adsorption double-column operation adopts two adsorption columns to alternatively carry out adsorption and regeneration steps, thereby saving the treatment time and improving the comfort level of patients; two or more inflammatory factor adsorption columns are connected in parallel and sequentially adsorb, so that the adsorption capacity is improved under the condition of not increasing the column pressure, and the requirements of different patients are met.
The utility model adopts the technical proposal that:
a combined immune-inflammation adsorption system comprises an arterial blood end, a venous blood end and a plasma end, wherein a plasma separator is connected between the arterial blood end and the venous blood end;
the input end of the plasma end is connected with the plasma separator, the output end of the plasma end is connected with the venous blood end, a first plasma bypass and a second plasma bypass are arranged on the plasma end, the first plasma bypass is connected with the inflammation factor adsorber in series, and the second plasma bypass is connected with the reproducible immune adsorption column in series;
the input end of the inflammation factor adsorber is respectively communicated with the first plasma bypass and the regeneration end of the adsorption device, and the output end of the inflammation factor adsorber is respectively communicated with the venous blood end and the waste liquid collector;
the input end of the reproducible immunoadsorption column is communicated with the second plasma bypass and the reproduction end of the adsorption device respectively, and the output end of the reproducible immunoadsorption column is communicated with the venous blood end and the waste liquid collector respectively;
and pipelines which are communicated with each other are arranged between the input end of the inflammation factor adsorber and the output end of the reproducible immune adsorption column, or pipelines which are communicated with each other are arranged between the output end of the inflammation factor adsorber and the input end of the reproducible immune adsorption column.
In some examples of a combined immune-inflammatory adsorption system, the arterial blood end includes an arterial blood input line, a blood pump, and an arterial pot.
In some examples of combined immuno-inflammatory adsorption systems, an anticoagulant injection port is connected to the arterial blood input line between the blood pump and the arterial kettle.
In some examples of the combined immuno-inflammatory adsorption system, the plasma end includes a plasma outlet line connected to a plasma separator, a plasma pump, a plasma pot, a connecting tube connected to a regenerable immuno-adsorption column and an inflammatory factor adsorber, and a plasma return line connected to a venous pot.
In some examples of the combined immune-inflammatory adsorption system, the output end of the inflammatory factor adsorber or the output end of the regenerable immune adsorption column is communicated with a venous pot at the venous blood end.
In some examples of a combined immuno-inflammatory adsorbent system, the regeneration end of the adsorbent device includes a flush fluid input line, a flush pump, an air trap, a flush fluid output line.
In some examples of a combined immune-inflammatory adsorption system, the regeneration end of the adsorption device has a liquid reservoir.
In some examples of a combined immuno-inflammatory adsorption system, the first plasma bypass is followed by 2 or more inflammatory factor adsorbers in parallel and/or the second plasma bypass is followed by 2 or more regenerable immunoadsorbent columns in parallel.
In some examples of a combined immuno-inflammatory adsorption system, the inflammatory factor adsorber is a neutral macroporous resin adsorber and/or the regenerable immunoadsorption column is a protein a immunoadsorption column.
The utility model has the advantages that:
some examples of the utility model can conveniently carry out immunoadsorption and inflammation adsorption treatment as required, and corresponding adsorption treatment is conveniently selected according to the specific conditions of patients, and is more efficient.
The utility model discloses a some examples, parallelly connected be provided with the inflammatory factor adsorber and can regenerate the immunoadsorption post, can adsorb and regenerate as required at the inflammatory factor adsorber of difference and the immunoadsorption post that can regenerate simultaneously, realize incessant processing.
The utility model discloses a regeneration step can be accomplished under the condition of not dismantling the adsorption column to some examples, satisfies the needs that continuously adsorb the purification.
Drawings
Fig. 1 is a schematic structural diagram of an embodiment of the present invention.
Fig. 2 is a schematic structural diagram of another embodiment of the present invention.
Fig. 3 is a schematic structural diagram of another embodiment of the present invention.
Reference numerals:
arterial blood end-1, blood pump-11, arterial kettle-12, anticoagulant filling opening-13
Plasma end-2, plasma pump-21, plasma pot-22, inflammation factor adsorber-23, reproducible immune adsorption column-24
Venous blood end-3, venous pot 31
Regeneration end-4 of adsorption device, liquid storage-41, flushing pump-42 and air-catching pot-43
Plasma separator-5
A waste liquid collector-6.
Detailed Description
Reference will now be made in detail to embodiments of the present invention, examples of which are illustrated in the accompanying drawings, wherein like or similar reference numerals refer to the same or similar elements or elements having the same or similar function throughout. The embodiments described below with reference to the accompanying drawings are exemplary only for the purpose of explaining the present invention, and should not be construed as limiting the present invention.
In the description of the present invention, it should be understood that the directional descriptions, such as the directions or positional relationships indicated by upper, lower, front, rear, left, right, etc., are based on the directions or positional relationships shown in the drawings, and are only for convenience of description and simplification of the description, but not for indicating or implying that the device or element referred to must have a specific direction, be constructed and operated in a specific direction, and thus should not be construed as limiting the present invention.
In the description of the present invention, a plurality of meanings are one or more, a plurality of meanings are two or more, and the terms greater than, smaller than, exceeding, etc. are understood as excluding the number, and the terms greater than, lower than, within, etc. are understood as including the number. If the first and second are described for the purpose of distinguishing technical features, they are not to be understood as indicating or implying relative importance or implicitly indicating the number of technical features indicated or implicitly indicating the precedence of the technical features indicated.
Furthermore, the terms "first", "second" and "first" are used for descriptive purposes only and are not to be construed as indicating or implying relative importance or implicitly indicating the number of technical features indicated. Thus, a feature defined as "first" or "second" may explicitly or implicitly include one or more features.
In the description of the present invention, it is to be noted that, unless otherwise explicitly specified or limited, the term "connected" is to be interpreted broadly, and may be, for example, a fixed connection or a movable connection, a detachable connection or a non-detachable connection, or an integral connection; may be mechanically connected, may be electrically connected or may be in communication with each other; they may be directly connected or indirectly connected through intervening media, or may be connected through one or more other elements or indirectly connected through one or more other elements or in an interactive relationship between two elements.
The following disclosure provides many different embodiments or examples for implementing different aspects of the invention.
Referring to fig. 1 to 3, a combined immune-inflammatory adsorption system comprises an arterial blood end 1, a venous blood end 3 and a plasma end 2, wherein a plasma separator 5 is connected between the arterial blood end 1 and the venous blood end 3;
the input end of the plasma end 2 is connected with the plasma separator 5, the output end is connected with the venous blood end 3, the plasma end 2 is provided with a first plasma bypass and a second plasma bypass, the first plasma bypass is connected with the inflammation factor adsorber 23 in series, and the second plasma bypass is connected with the reproducible immune adsorption column 24 in series;
the input end of the inflammatory factor adsorber 23 is communicated with the first plasma bypass, and the output ends of the inflammatory factor adsorber 23 are respectively communicated with the venous blood end 3;
the input end of the reproducible immune adsorption column 24 is respectively communicated with the second blood plasma bypass and the reproduction end 4 of the adsorption device, and the output end of the reproducible immune adsorption column 24 is respectively communicated with the venous blood end 3 and the waste liquid collector 6;
and mutually communicated pipelines are arranged between the input end of the inflammation factor adsorber 23 and the output end of the reproducible immunological adsorption column 24, or mutually communicated pipelines are arranged between the output end of the inflammation factor adsorber 23 and the input end of the reproducible immunological adsorption column 24.
The output end of the inflammation factor adsorber 23 and the output end of the reproducible immune adsorption column 24 can be directly communicated with the venous blood end 3, or can be communicated with the venous blood end 3 through the output end of the inflammation factor adsorber 23 or the output end of the reproducible immune adsorption column 24 after being connected in series. When the inflammatory factor adsorber 23 and the regenerable immunoadsorption column 24 are connected in series, the inflammatory factor adsorber 23 may precede the regenerable immunoadsorption column 24, or the regenerable immunoadsorption column 24 may precede the inflammatory factor adsorber.
In some examples of a combined immuno-inflammatory adsorption system, the arterial blood end 1 includes an arterial blood input line, a blood pump 11, and an arterial pot 12. In use, arterial blood passes through the arterial blood inlet line and enters the arterial pot 12 under the action of the blood pump 11. The arterial pot 12 has a cushioning effect which helps to keep the system running continuously.
In some examples of combined immuno-inflammatory adsorption systems, an anticoagulant fill port 13 is connected to the arterial blood input line between the blood pump 11 and the arterial kettle 12. A certain amount of anticoagulant is injected through the anticoagulant injection port 13, which is beneficial to maintaining the normal operation of the adsorption system.
In some examples of the combined immuno-inflammatory adsorption system, the plasma end 2 includes a plasma outlet line connected to the plasma separator 5, a plasma pump 21, a plasma pot 22, a connecting tube connected to the regenerable immuno-adsorption column 24 and the inflammatory factor adsorber 23, and a plasma return line connected to the venous pot 31. The drawn plasma flows into the plasma kettle 22 by the action of the plasma pump 21, and further flows into the reproducible immune adsorption column 24 and the inflammatory factor adsorber 23 for adsorption. The plasma kettle 22 has a certain buffer function, which is beneficial to keeping the system running continuously.
In some examples of the combined immuno-inflammatory adsorption system, the output of the inflammatory factor adsorber 23 or the output of the regenerable immuno-adsorbent column 24 is in communication with the venous pot 31 of the venous blood end 3. The venous pot 31 has a certain buffer function, which is beneficial to keeping the system running continuously.
In some examples of a combined immuno-inflammatory adsorbent system, the adsorbent regeneration end 4 includes a flushing liquid input line, a flushing pump 42, an air trap 43, a flushing liquid output line. When in use, various liquids enter the air-catching pot 43 under the action of the liquid pump, and after further eliminating the gas in the liquids, the inflammation factor adsorber 23 and/or the renewable immunoadsorption column 24 are pre-flushed or regenerated according to the requirements.
In some examples of a combined immuno-inflammatory adsorbent system, the adsorbent device regeneration end 4 has a fluid reservoir 41, including but not limited to, a saline, equilibration fluid and eluent reservoir. The specific types can be selected according to the specific types of the inflammatory factor adsorber 23 and the regenerable immunoadsorption column 24.
The inflammatory factor adsorber 23 and the regenerable immunoadsorption column 24 may be an inflammatory factor adsorber 23 and a regenerable immunoadsorption column 24 known in the art. In some examples of combined immuno-inflammatory adsorption systems, the first plasma bypass is followed by 2 or more inflammatory factor adsorbers 23 in parallel and/or the second plasma bypass is followed by 2 or more regenerable immunoadsorbent columns 24 in parallel. When in use, according to the specific needs of treatment, different numbers of inflammatory factor adsorbers 23 and reproducible immune adsorption columns 24 are matched. For example, the adsorption treatment time of the typical inflammatory factor adsorber 23 is 2.5 h, and the single treatment requires 5 hours of adsorption, 2 inflammatory factor adsorbers 23 may be connected in parallel, and after one inflammatory factor adsorber 23 is saturated in adsorption, the other inflammatory factor adsorber 23 is switched. The regenerable immunoadsorption columns 24 are regenerable, and different quantities of regenerable immunoadsorption columns 24 can be configured according to different adsorption time and regeneration time, so that at least one regenerable immunoadsorption column 24 is in an available state in the regeneration process.
In some examples of a combined immuno-inflammatory adsorption system, the inflammatory factor adsorber 23 is a neutral macroporous resin adsorber and/or the regenerable immunoadsorbent column 24 is a protein a immunoadsorbent column.
In the following examples, the inflammatory factor adsorber 23 is a neutral macroporous resin adsorber, and the regenerable immunoadsorption column 24 is a protein a immunoadsorption column, unless otherwise specified.
Example 1
Referring to fig. 1, a combined immune-inflammatory adsorption system comprises an arterial blood end 1, a venous blood end 3 and a plasma end 2, wherein a plasma separator 5 is connected between the arterial blood end 1 and the venous blood end 3;
the arterial blood end 1 comprises an arterial blood input pipeline, a blood pump 11 and an arterial pot 12, wherein an anticoagulant filling opening 13 is connected to the arterial blood input pipeline between the blood pump 11 and the arterial pot 12;
the plasma end 2 comprises a plasma leading-out pipeline connected with the plasma separator 5, a plasma pump 21, a plasma pot 22, a connecting pipe connected with a reproducible immune adsorption column 24 and an inflammation factor adsorber 23, and a plasma return pipeline connected with the venous pot 31, the input end of the plasma end 2 is connected with the plasma separator 5, the output end of the plasma end is connected with the venous blood end 3, a first plasma bypass and a second plasma bypass are arranged on the plasma end 2, the first plasma bypass is connected with the inflammation factor adsorber 23 in series, and the second plasma bypass is connected with the reproducible immune adsorption column 24 in series;
the input end of the reproducible immune adsorption column 24 is respectively communicated with the second blood plasma bypass and the reproduction end 4 of the adsorption device, and the output end of the reproducible immune adsorption column 24 is respectively communicated with the input end of the inflammation factor adsorber 23 and the waste liquid collector 6;
the input end of the inflammation factor adsorber 23 is respectively communicated with the first plasma bypass and the output end of the reproducible immunoadsorption column 24, and the output end of the inflammation factor adsorber 23 is respectively communicated with the venous pot 31 of the venous blood end 3;
the regeneration end 4 of the adsorption device comprises a liquid storage 41, a flushing liquid input pipeline, a flushing pump 42, an air trapping pot 43 and a flushing liquid output pipeline.
In one mode of use, the whole combined immune-inflammatory adsorption system is pre-flushed, after the pre-flushing is finished, the blood plasma led out from the blood plasma separator 5 sequentially passes through the reproducible immune adsorption column 24 and the inflammatory factor adsorber 23, and after the adsorption is finished, the blood plasma enters the venous pot and is finally led into the body. When the reproducible immune adsorption column 24 needs to be reproduced, the blood plasma is directly introduced into the inflammation factor adsorber 23 for inflammation factor adsorption, the reproducible immune adsorption column 24 is reproduced by using the reproduction end 4 of the adsorption device, and the waste liquid is collected in the waste liquid collector 6. The operation mode is suitable for the condition of less immune adsorption, and can realize the uninterrupted adsorption of inflammatory factors and the intermittent adsorption of immune factors.
By exchanging the positions of the inflammation factor adsorber 23 and the regenerable immunoadsorption column 24 while adaptively adjusting the piping of the regeneration end 4 of the adsorption device, another combined immuno-inflammatory adsorption system can be obtained.
Example 2
Referring to fig. 2, a combined immune-inflammatory adsorption system comprises an arterial blood end 1, a venous blood end 3 and a plasma end 2, wherein a plasma separator 5 is connected between the arterial blood end 1 and the venous blood end 3;
the arterial blood end 1 comprises an arterial blood input pipeline, a blood pump 11 and an arterial pot 12, wherein an anticoagulant filling opening 13 is connected to the arterial blood input pipeline between the blood pump 11 and the arterial pot 12;
the plasma end 2 comprises a plasma leading-out pipeline connected with the plasma separator 5, a plasma pump 21, a plasma kettle 22, a connecting pipe connected with a reproducible immune adsorption column 24 and an inflammation factor adsorber 23, and a plasma return pipeline connected with a venous kettle 31, wherein the input end of the plasma end 2 is connected with the plasma separator 5, the output end of the plasma end is connected with a venous blood end 3, a first plasma bypass and a second plasma bypass are arranged on the plasma end 2, the first plasma bypass is connected with the inflammation factor adsorber 23 in series, and the second plasma bypass is connected with 2 reproducible immune adsorption columns 24 connected in parallel in series;
the input end of the reproducible immune adsorption column 24 is respectively communicated with the second blood plasma bypass and the reproduction end 4 of the adsorption device, and the output end of the reproducible immune adsorption column 24 is respectively communicated with the input end of the inflammation factor adsorber 23 and the waste liquid collector 6;
the input end of the inflammation factor adsorber 23 is respectively communicated with the first plasma bypass and the output end of the reproducible immunoadsorption column 24, and the output end of the inflammation factor adsorber 23 is communicated with the venous pot 31 of the venous blood end 3;
the regeneration end 4 of the adsorption device comprises a liquid storage 41, a flushing liquid input pipeline, a flushing pump 42, an air trapping pot 43 and a flushing liquid output pipeline.
In one mode of use, the whole combined immune-inflammatory adsorption system is pre-flushed, after the pre-flushing is finished, the blood plasma led out from the blood plasma separator 5 sequentially passes through the reproducible immune adsorption column 24 and the inflammatory factor adsorber 23, and after the adsorption is finished, the blood plasma enters the venous pot and is finally led into the body. When one reproducible immune adsorption column 24 needs to be reproduced, the blood plasma is introduced into the other reproducible immune adsorption column 24, the reproducible immune adsorption column 24 is reproduced by using the reproduction end 4 of the adsorption device, and the waste liquid is collected in the waste liquid collector 6. In this way, uninterrupted immunoadsorption and inflammatory factor adsorption can be achieved.
By exchanging the positions of the inflammation factor adsorber 23 and the regenerable immune adsorption column 24 and simultaneously adaptively adjusting the pipeline of the regeneration end 4 of the adsorption device, another combined immune-inflammation adsorption system can be obtained.
Example 3
Referring to fig. 3, a combined immune-inflammatory adsorption system comprises an arterial blood end 1, a venous blood end 3 and a plasma end 2, wherein a plasma separator 5 is connected between the arterial blood end 1 and the venous blood end 3;
the arterial blood end 1 comprises an arterial blood input pipeline, a blood pump 11 and an arterial pot 12, wherein an anticoagulant filling opening 13 is connected to the arterial blood input pipeline between the blood pump 11 and the arterial pot 12;
the plasma end 2 comprises a plasma leading-out pipeline connected with the plasma separator 5, a plasma pump 21, a plasma kettle 22, a connecting pipe connected with a reproducible immune adsorption column 24 and an inflammation factor adsorber 23, and a plasma return pipeline connected with a venous kettle 31, wherein the input end of the plasma end 2 is connected with the plasma separator 5, the output end of the plasma end is connected with a venous blood end 3, a first plasma bypass and a second plasma bypass are arranged on the plasma end 2, the first plasma bypass is connected with 2 inflammation factor adsorbers 23 in parallel in series, and the second plasma bypass is connected with 2 reproducible immune adsorption columns 24 in parallel in series;
the input end of the reproducible immune adsorption column 24 is respectively communicated with the second blood plasma bypass and the reproduction end 4 of the adsorption device, and the output end of the reproducible immune adsorption column 24 is respectively communicated with the input end of the inflammation factor adsorber 23 and the waste liquid collector 6;
the input end of the inflammation factor adsorber 23 is respectively communicated with the first plasma bypass and the output end of the reproducible immunoadsorption column 24, and the output end of the inflammation factor adsorber 23 is communicated with the venous pot 31 of the venous blood end 3;
the regeneration end 4 of the adsorption device comprises a liquid storage 41, a flushing liquid input pipeline, a flushing pump 42, an air trapping pot 43 and a flushing liquid output pipeline.
In one mode of use, the whole combined immune-inflammatory adsorption system is pre-flushed, after the pre-flushing is finished, the plasma led out from the plasma separator 5 passes through the reproducible immune adsorption column 24 and the inflammatory factor adsorber 23 in sequence, enters the venous pot after the adsorption is finished, and is finally led into the body. When one reproducible immune adsorption column 24 needs to be reproduced, introducing the blood plasma into the other reproducible immune adsorption column 24, reproducing the reproducible immune adsorption column 24 by using the reproduction end 4 of the adsorption device, and collecting the waste liquid in the waste liquid collector 6; when the adsorption of one inflammatory factor adsorber 23 is saturated, the operation is switched to the other inflammatory factor adsorber 23. In this way, uninterrupted immunoadsorption and inflammatory factor adsorption can be achieved, and the method is suitable for the situation that inflammatory factor adsorption needs to be carried out for a long time.
By exchanging the positions of the inflammation factor adsorber 23 and the regenerable immunoadsorption column 24 while adaptively adjusting the piping of the regeneration end 4 of the adsorption device, another combined immuno-inflammatory adsorption system can be obtained.
The above is a further detailed description of the present invention and should not be considered as limiting the practice of the present invention. To the ordinary skilled person in the technical field that the utility model belongs to, the simple deduction or the replacement that does not depart from the inventive concept is all within the scope of the utility model.
Claims (10)
1. A combined immune-inflammation adsorption system comprises an arterial blood end, a venous blood end and a plasma end, wherein a plasma separator is connected between the arterial blood end and the venous blood end; it is characterized in that the preparation method is characterized in that,
the input end of the plasma end is connected with the plasma separator, the output end of the plasma end is connected with the venous blood end, a first plasma bypass and a second plasma bypass are arranged on the plasma end, the first plasma bypass is connected with the inflammation factor adsorber in series, and the second plasma bypass is connected with the reproducible immune adsorption column in series;
the input end of the inflammation factor adsorber is communicated with the first plasma bypass, and the output end of the inflammation factor adsorber is communicated with the venous blood end;
the input end of the reproducible immunoadsorption column is communicated with the second plasma bypass and the reproduction end of the adsorption device respectively, and the output end of the reproducible immunoadsorption column is communicated with the venous blood end and the waste liquid collector respectively;
and pipelines which are communicated with each other are arranged between the input end of the inflammation factor adsorber and the output end of the reproducible immunoadsorption column, or pipelines which are communicated with each other are arranged between the output end of the inflammation factor adsorber and the input end of the reproducible immunoadsorption column.
2. The combined immuno-inflammatory adsorption system of claim 1, wherein the arterial blood end includes an arterial blood input line, a blood pump, and an arterial pot.
3. The combined immuno-inflammatory adsorption system of claim 2, wherein an anticoagulant fill port is connected to the arterial blood input line between the blood pump and the arterial kettle.
4. The combined immune-inflammatory adsorption system of claim 1 wherein the plasma port comprises a plasma outlet line for connection to a plasma separator, a plasma pump, a plasma pot, a connection line for connection to a regenerable immune adsorption column and an inflammatory factor adsorber, and a plasma return line for connection to a venous pot.
5. The combined immuno-inflammatory adsorption system according to any one of claims 1 to 4, wherein the venous blood end includes a venous blood return line and a venous pot.
6. The combined immuno-inflammatory adsorption system of claim 5, wherein the output of the inflammatory factor adsorber or the output of the regenerable immunoadsorbent column is in communication with the venous pot of the venous blood end.
7. The combined immuno-inflammatory adsorbent system according to any one of claims 1 to 4, wherein the regeneration end of the adsorbent device comprises a flushing liquid input line, a flushing pump, an air trap, a flushing liquid output line.
8. The combined immuno-inflammatory adsorbent system of claim 7, wherein the regeneration end of the adsorbent device has a reservoir of liquid.
9. The combined immuno-inflammatory adsorption system according to any one of claims 1 to 4, wherein the first plasma bypass is followed by 2 or more inflammatory factor adsorbers in parallel and/or the second plasma bypass is followed by 2 or more regenerable immunoadsorbent columns in parallel.
10. The combined immuno-inflammatory adsorption system according to any one of claims 1 to 4, wherein the inflammatory factor adsorber is a neutral macroporous resin adsorber and/or the regenerable immunoadsorption column is a protein A immunoadsorption column.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202222334289.3U CN218833279U (en) | 2022-09-02 | 2022-09-02 | Combined immune-inflammation adsorption system |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202222334289.3U CN218833279U (en) | 2022-09-02 | 2022-09-02 | Combined immune-inflammation adsorption system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN218833279U true CN218833279U (en) | 2023-04-11 |
Family
ID=87284519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202222334289.3U Active CN218833279U (en) | 2022-09-02 | 2022-09-02 | Combined immune-inflammation adsorption system |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN218833279U (en) |
-
2022
- 2022-09-02 CN CN202222334289.3U patent/CN218833279U/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7758533B2 (en) | Hemofiltration systems, methods and devices for treatment of chronic and acute diseases | |
| US8771513B2 (en) | Regeneratable filter for extracorporal treatment of liquids containing particles and use thereof | |
| CN107583120B (en) | Plasma exchange dialysis adsorption system | |
| CN216676557U (en) | Bidirectional switchable immunoadsorption system | |
| CN108310503A (en) | A kind of Almightiness type plasma purification system based on centrifugal separation plasma method | |
| CN205073379U (en) | Plasma exchange adsorbs filters clean system | |
| CN218833279U (en) | Combined immune-inflammation adsorption system | |
| CN105107042A (en) | Blood purifier | |
| CN2822644Y (en) | Protein A immunoadsorbent system | |
| CN105107041A (en) | Blood purifier and displacement method thereof | |
| CN204521750U (en) | A kind of artificial liver and blood purification system | |
| CN106110424A (en) | Female tire Rh blood group incompatibility immunoadsorption therapy instrument | |
| CN106377812B (en) | A kind of plasma circulation acceleration purification system | |
| CN208552666U (en) | A kind of plasma exchange dialysis adsorption system | |
| CN211884744U (en) | Continuous albumin dialysis adsorption purification system | |
| CN212699875U (en) | Plasma replacement adsorption system | |
| DE102004037475A1 (en) | Filter system for the membrane-separated, adsorptive treatment of particle-containing liquids | |
| CN216394901U (en) | Double-column combined immunoadsorption system | |
| CN215780978U (en) | Connecting pipe used on protein A adsorber | |
| CN220293913U (en) | Dialysis is with multi-functional dialysis machine of two blood pumps | |
| CN208552669U (en) | A kind of Almightiness type plasma purification system based on centrifugal separation plasma method | |
| CN219042994U (en) | Double-venous-kettle blood purification pipeline system | |
| CN201862019U (en) | Connecting bag special for matched plasma exchange, filtration and adsorption treatment | |
| CN210583234U (en) | Blood component separation and multiple adsorption system of plasma molecule | |
| CN217612229U (en) | Blood purification system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| GR01 | Patent grant |